NIA Impact Advisors’s ImmunityBio IBRX Stock Holding History

NIA Impact Advisors’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.37M	Buy	270,167 +1,370	+0.5%	+$10.4K	0.98%	40
2026 Q1	$2.06M	Buy	+268,797	New	+$1.84M	0.92%	37

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

NIA Impact Advisors's IBRX Position: Q2 2026 in Review

NIA Impact Advisors increased its ImmunityBio (IBRX) stake by 0.51% in Q2 2026, buying an estimated $10.4K and bringing the position to 270,167 shares worth $2.37M. The position accounts for 0.98% of the portfolio, ranked #40.

NIA Impact Advisors first reported a position in IBRX in Q1 2026 and has held it in 2 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

NIA Impact Advisors held 270,167 shares of ImmunityBio worth $2.37M as of Q2 2026.
NIA Impact Advisors bought 1,370 ImmunityBio shares in Q2 2026, an estimated $10.4K.
ImmunityBio made up 0.98% of NIA Impact Advisors's portfolio in Q2 2026, its #40 holding.
NIA Impact Advisors first reported a position in ImmunityBio in Q1 2026 and has held it in 2 quarters since.
405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on NIA Impact Advisors's 13F filing for Q2 2026, filed 3 Aug 2026.